Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Cancer is the second leading cause of death after heart disease in the US Chemotherapy is a mainstay of treatment after surgical removal of tumors but the balance of clinical benefit versus disabling or life threatening side effects is often uncertain Genotyping of cancers to identify mutated oncogenes has enabled an era of targeted therapy Drugs targeting ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  2. RADIOGRAPHIC CONTRAST TO DIFFERENTIATE CAVITATED FROM NON-CAVITATED DENTAL CARIES

    SBC: FIREFLY HEALTH INNOVATIONS NE, INC.            Topic: NIDCR

    DESCRIPTION provided by applicant This project aims to improve the accuracy of tests for early tooth decay dental caries specifically for interproximal surfaces where the posterior teeth abut one another In these regions there is no physical space to visually inspect or probe for caries Instead dentists rely on bitewing X rays BWs But dentists cannot tell whether lucencies observed ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIDDK

    DESCRIPTION provided by applicant Non alcoholic steatohepatitis NASH is characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosis and cirrhosis and high mortality rates NASH is frequently associated with other common metabolic abnormalities such as insulin resistance and visceral obesity Liver transplantation is curren ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Brain penetrant Hsp90 inhibitors for Alzheimer's disease

    SBC: YUMA THERAPEUTICS CORPORAITON            Topic: NIA

    DESCRIPTION provided by applicant Neurodegeneration in Alzheimerandapos s disease AD may result from deposition of A as plaques in brain tissue However less effort has been made to elucidate the role of tau containing neurofibrillary tangles NFTs in AD Accumulating evidence suggests that tau containing NFTs is an important component in the initiation and progression of AD and other neu ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Extending Genome-Phenome Analysis

    SBC: SimulConsult, Inc.            Topic: 172

    DESCRIPTION provided by applicant The declining cost of whole exome sequencing WES is nearing the point at which the spread of WES into clinical practice will be limited largely by the cost of interpreting the results and comparing them to the patientandapos s clinical findings This project builds on our demonstrated capability to reduce this interpretation cost by pairing our diagnostic sof ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a clinical hemoglobin modulator

    SBC: Phoenicia Biosciences, Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant The thalassemias and sickle cell disease are serious genetic blood diseases which are WHO designated as a growing global health burden The disorders decrease production or alter structure of the b chain of adult hemoglobin A and are characterized by anemia chronic organ damage and early mortality HbF is another type of normal hemoglobin which is suppres ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Slip Flow Chromatography

    SBC: BIOVIDRIA, INC.            Topic: 100

    DESCRIPTION provided by applicant The goal of this STTR Phase II collaboration between Purdue University and bioVidria Inc is to commercialize disruptive new technology for protein chromatography and then maximize its impact by serving the fastest growing segment of the pharmaceutical industry protein drugs The product is a reversed phase chromatography column that uses silica particles of ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Emergency Operations Plans for Individuals with Disabilities

    SBC: Praxis            Topic: NICHD

    DESCRIPTION provided by applicant The proposed project is designed to fill an important yet unmet need by developing an online education program using simulations and scenario based learning to reach all public health and safety emergency responders and students responsible for emergency planning with and response for individuals with disabilities In Phase II the applicant organization P ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government